siRNA-mediated inhibition of angiogenesis

Expert Opinion on Biological Therapy

Volumn 5, Issue 3, 2005, Pages 359-368

  Schiffelers, Raymond M ^a   Van Rooy, Inge ^a   Storm, Gert ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Angiogensis; siRNA

Indexed keywords

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; ATELOCOLLAGEN; ENDOSTATIN; FUMAGILLIN; GROWTH FACTOR; LIPOSOME; NUCLEIC ACID; POLYMER; SMALL INTERFERING RNA;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; CELL TYPE; DRUG CLASSIFICATION; GENE DELIVERY SYSTEM; GENE FUNCTION; GENE SEQUENCE; GENE SILENCING; GENE TARGETING; HUMAN; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; TUMOR;

ANIMALS; GENE SILENCING; GENE TARGETING; HUMANS; NEOVASCULARIZATION, PHYSIOLOGIC; RNA, SMALL INTERFERING;

EID: 17144418496     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.5.3.359     Document Type: Review

References (90)

1. NAPOLI C, LEMIEUX C, JORGENSEN R: Introduction of a chimeric chalcone synthase gene into petunia results in reversible co-suppression of homologous genes in trans. Plant Cell (1990) 2(4):279-289.
2. FIRE A, XU S, MONTGOMERY MK et al: Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature (1998) 391(6669):806-811. Landmark paper on the use of RNAi in animals.
3. KENNERDELL JR, CARTHEW RW: Heritable gene silencing in Drosophila using double-stranded RNA. Nat. Biotechnol. (2000) 18(8):896-898.
4. AGRAWAL N, DASARADHI PV, MOHMMED A et al.: RNA interference: biology, mechanism, and applications. Microbiol. Mol. Biol. Rev. (2003) 67(4):657-685.
5. ARENZ C, SCHEPERS U: RNA interference: from an ancient mechanism to a state of the art therapeutic application? Naturwissenschaften (2003) 90(8):345-359.
6. SCHERR M, MORGAN MA, EDER M: Gene silencing mediated by small interfering RNAs in mammalian cells. Curr. Med. Chem. (2003) 10(3):245-256.
7. SUSI P, HOHKURI M, WAHLROOS T, KILBY NJ: Characteristics of RNA silencing in plants: similarities and differences across kingdoms. Plant Mol. Biol. (2004) 54(2):157-174.
8. VERMA NK, DEY CS: RNA-mediated gene silencing: mechanisms and its therapeutic applications. J. Clin. Pharm. Ther. (2004) 29(5):395-404.
9. TIJSTERMAN M, PLASTERK RH: Dicers at RISC; the mechanism of RNAi. Cell (2004) 117(1):1-3. Overview of the molecular players involved in RNAi.
10. OKAMURA K, ISHIZUKA A, SIOMI H, SIOMI MC: Distinct roles for Argonaute proteins in small RNA-directed RNA cleavage pathways. Genes Den (2004) 18(14):1655-1666.
11. PELLINO JL, SONTHEIMER EJ: R2D2 leads the silencing trigger to mRNA's death star. Cell (2003) 115(2):132-133.
12. MARTINEZ J, PATKANIOWSKA A, URLAUB H, LUHRMANN R, TUSCHLT: Single-stranded antisense siRNAs guide target RNA cleavage in RNAi. Cell (2002) 110(5):563-574.
13. KAWASAKI H, TAIRA K: Induction of DNA methylation and gene silencing by short interfering RNAs in human cells. Nature (2004) 431(7005):211-217.
14. MORRIS KV, CHAN SW, JACOBSEN SE, LOONEY DJ: Small interfering RNA-induced transcriptional gene silencing in human cells. Science (2004) 305(5688):1289-1292.
15. SAUNDERS LR, BARBER GN: The dsRNA binding protein family: critical roles, diverse cellular functions. FASEB J. (2003) 17(9):961-983.
16. SLEDZ CA, WILLIAMS BR: RNA interference and double-stranded-RNA-activated pathways. Biochem. Soc. Trans. (2004) 32(Pt 6):952-956.
17. PERSENGIEV SP, ZHU X, GREEN MR: Nonspecific, concentration-dependent stimulation and repression of mammalian gene expression by small interfering RNAs (siRNAs). RNA (2004) 10(1):12-18.
18. SLEDZ CA, HOLKO M, DE VEER MJ, SILVERMAN RH, WILLIAMS BR: Activation of the Interferon system by short-interfering RNAs. Nat. Cell Biol. (2003) 5(9):834-839.
19. TIJSTERMAN M, MAY RC, SIMMER F, OKIHARA KL, PLASTERK RH: Genes required for systemic RNA interference in Caenorhabditis elegans. Curr. Biol. (2004) 14(2):111-116.
20. FEINBERG EH, HUNTER CP: Transport of dsRNA into cells by the transmembrane protein SID-1. Science (2003) 301(5639):1545-1547.
21. WINSTON WM, MOLODOWITCH C, HUNTER CP: Systemic RNAi in C. elegans requires the putative transmembrane protein SID-1. Science (2002) 295(5564):2456-2459.
22. SIJEN T, FLEENOR J, SIMMER F et al.: On the role of RNA amplification in dsRNA-triggercd gene silencing. Cell (2001) 107(4):465-476.
23. VAN ROESSEL P, BRAND AH: Spreading silence with Sid. Genome Biol. (2004) 5(2):208.
24. MAINE EM: RNAi As a tool for understanding germline development in Caenorhabditis elegans: uses and cautions. Dev. Biol. (2001) 239(2):177-189.
25. BARGMANN CI: High-throughput reverse genetics: RNAi screens in Caenorhabditis elegans. Genome Biol. (2001) 2(2):REVIEWS1005.
26. TIMMONS L, COURT DL, FIRE A: Ingestion of bacterially expressed dsRNAs can produce specific and potent genetic interference in Caenorhabditis elegans. Gene (2001) 263(1-2):103-112.
27. TIMMONS L, FIRE A: Specific interference by ingested dsRNA. Nature (1998) 395(6705):854.
28. DEVERAUX QL, AZA-BLANC P, WAGNER KW et al.: Exposing oncogenic dependencies for cancer drug target discovery and validation using RNAi. Semin. Cancer Biol. (2003) 13(4):293-300.
29. MOUSSES S, CAPLEN NJ, CORNELISON R et al.: RNAi microarray analysis in cultured mammalian cells. Genome Res. (2003) 13(10):2341-2347.
30. ARTS GJ, LANGEMEIJER E, TISSINGH R et al.: Adenoviral vectors expressing siRNAs for discovery and validation of gene function. Genome Res. (2003) 13(10):2325-2332.
31. DORSETT Y, TUSCHL T: siRNAs: applications in functional genomics and potential as therapeutics. Nat. Rev. Drug Discov. (2004) 3(4):318-329. Review detailing the possible uses of siRNA.
32. DEVROE E, SILVER PA: Therapeutic potential of retroviral RNAi vectors. Expert Opin. Biol. Ther. (2004) 4(3):319-327.
33. LU PY, XIE FY, WOODLE MC: siRNA-mediated antitumorigenesis for drug target validation and therapeutics. Curr. Opin. Mol. Ther. (2003) 5(3):225-234.
34. KRANENBURG O, GEBBINK MF, VOEST EE: Stimulation of angiogenesis by Ras proteins. Biochim. Biophys. Acta (2004) 1654(1):23-37.
35. MOUSA SA, MOUSA AS: Angiogenesis inhibitors: current & future directions. Curr. Pharm. Des. (2004) 10(1):1-9.
36. PAROO Z, COREY DR: Challenges for RNAi in vivo. Trends Biotech. (2004) 22(8):390-394.
37. GILMORE IR, FOX SP, HOLLINS AJ, SOHAIL M, AKHTAR S: The design and exogenous delivery of siRNA for post-transcriptional gene silencing. J. Drug Target. (2004) 12(6):315-340.
38. WALL NR, SHI Y: Small RNA: can RNA interference be exploited for therapy? Lancet (2003) 362(9393):1401-1403.
39. GRIFFIOEN AW, MOLEMA G: Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol. Rev. (2000) 52(2):237-268. Review on the potential of angiogenesis targeted therapies.
40. SCHLINGEMANN RO: Role of growth factors and the wound healing response in age-related macular degeneration. Graefes Arch. Clin. Exp. Ophthalmol. (2004) 242(1):91-101.
41. GRANT MB, AFZAL A, SPOERRI P et al.: The role of growth factors in the pathogenesis of diabetic retinopathy. Expert Opin. Investig. Drugs (2004) 13(10):1275-1293.
42. MIDDLETON J, AMERICH L, GAYON R et al.: Endothelial cell phenotypes in the rheumatoid synovium: activated, angiogenic, apoptotic and leaky. Arthritis Res. Ther. (2004) 6(2):60-72.
43. BIAN XW, CHEN JH, JIANG XF et al: Angiogenesis as an immunopharmacologic target in inflammation and cancer. Int. Immunopharmacol. (2004) 4(12):1537-1547.
44. SATO Y: Molecular diagnosis of tumor angiogenesis and anti-angiogenic cancer therapy. Int. J. Clin. Oncol. (2003) 8(4):200-206.
45. SUHARDJA A, HOFFMAN H: Role of growth factors and their receptors in proliferation of microvascular endothelial cells. Microsc. Res. Tech. (2003) 60(1):70-75.
46. TSOPANOGLOU NE, MARAGOUDAKlS ME: Role of thrombin in angiogenesis and tumor progression. Semin. Thromb. Hemost. (2004) 30(1):63-69.
47. JIN H, VARNER J: Integrins: roles in cancer development and as treatment targets. Br. J. Cancer (2004) 90(3):561-565.
48. SEIKI M, MORI H, KAJITA M, UEKITA T, ITOH Y: Membrane-type 1 matrix metalloproteinase and cell migration. Biochem. Soc. Symp. (2003) (70):253-262.
49. GERHARDT H, BETSHOLTZ C: Endothelial-pericyte interactions in angiogenesis. Cell Tissue Res. (2003) 314(1):15-23.
50. SCAVELLI C, WEBER E, AGLIANO M et al.: Lymphatics at the crossroads of angiogenesis and lymphangiogenesis. J. Anat. (2004) 204(6):433-449.
51. ALITALO K, CARMELIET P: Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cell (2002) 1(3):219-227.
52. LOHELA M, SAARISTO A, VEIKKOLA T, ALITALO K: Lymphangiogenic growth factors, receptors and therapies. Thromb. Haemost. (2003) 90(2):167-184.
53. SHU X, WU W, MOSTELLER RD, BROEK D: Sphingosine kinase mediates vascular endothelial growth factor-induced activation of ras and mitogen-activated protein kinases. Mol. Cell. Biol. (2002) 22(22):7758-7768.
54. PETROVIC N, BHAGWAT SV, RATZAN WJ, OSTROWSKI MC, SHAPIRO LH: CD13/APN transcription is induced by RAS/MAPK-mediated phosphorylation of Ets-2 in activated endothelial cells. J. Biol. Chem. (2003) 278(49):49358-49368.
55. SOWTER HM, RAVAL RR, MOORE JW, RATCLIFFE PJ, HARRIS AL: Predominant role of hypoxia-inducible transcription factor (Hif)-1alpha versus Hif-2alpha in regulation of the transcriptional response to hypoxia. Cancer Res. (2003) 63(19):6130-6134.
56. ZHANG L, YANG N, MOHAMED-HADLEY A, RUBIN SC, COUKOS G: Vector-based RNAi, a novel tool for isoform-specific knock-down of VEGF and anti-angiogenesis gene therapy of cancer. Biochem. Biophys. Res. Commun. (2003) 303(4):1169-1178.
57. MAZZANTl CM, TANDLE A, LORANG D et al.: Early genetic mechanisms underlying the inhibitory effects of endostatin and fumagillin on human endothelial cells. Genome Res. (2004) 14(8):1585-1593.
58. NAIK MU, VUPPALANCHI D, NAIK UP: Essential role of junctional adhesion molecule-1 in basic fibroblast growth factor-induced endothelial cell migration. Arterioscler. Thromb. Vasc. Biol. (2003) 23(12):2165-2171.
59. NAGASHIMA K, ENDO A, OGITA H et al.: Adaptor protein Crk is required for ephrin-B1-induced membrane ruffling and focal complex assembly of human aortic endothelial cells. Mol. Biol. Cell (2002) 13(12):4231-4242.
60. SULLIVAN DC, HUMINIECKI L, MOORE JW et al.: EndoPD1, a novel protein-disulfide isomerase-like protein that is preferentially expressed in endothelial cells acts as a stress survival factor. J. Biol. Chem. (2003) 278(47):47079-47088.
61. BALDANZI G, MITOLA S, CUTRUPI S et al: Activation of diacylglycerol kinase alpha is required for VEGF-induced angiogenic signaling in vitro. Oncogene (2004) 23(28):4828-4838.
62. BRUHL T, URBICH C, AICHER D et al.: Homeobox A9 transcriptionally regulates the EphB4 receptor to modulate endothelial cell migration and tube formation. Circ. Res. (2004) 94(6):743-751.
63. ZHOU X, STUART A, DETTIN LE et al.: Desmoplakin is required for microvascular tube formation in culture. J. Cell Sci. (2004) 117(Pt 15):3129-3140.
64. CONRAD C, ERFLE H, WARNAT P et al.: Automatic identification of subcellular phenotypes on human cell arrays. Genome Res. (2004) 14(6):1130-1136.
65. SILVA JM, MIZUNO H, BRADY A, LUCITO R, HANNON GJ: RNA interference microarrays: high-throughput loss-of-funcnon genetics in mammalian cells. Proc. Natl. Acad. Sci. USA (2004) 101(17):6548-6552.
66. SUGIMOTO A: High-throughput RNAi in Caenorhabditis elegans: genome-wide screens and functional genomics. Differentiation (2004) 72(2-3):81-91.
67. SHIBUYA M: VEGF-receptor inhibitors for anti-angiogenesis. Nippon Yakurigaku Zasshi (2003) 122(6):498-503.
68. ZACHARY I: VEGF signalling: integration and multi-tasking in endothelial cell biology. Biochem. Soc. Trans. (2003) 31(Pt 6):1171-1177.
69. HARRY LE, PALEOLOG EM: From the cradle to the clinic: VEGF in developmental, physiological, and pathological angiogenesis. Birth Defects Res. Part C Embryo Today (2003) 69(4):363-374.
70. UEDA Y, YAMAGISHI T, IKEYA H et al.: VGA1155, a novel binding antagonist of VEGF, inhibits angiogenesis in vitro and in vivo. Anti-Cancer Res. (2004) 24(5A):3009-3017.
71. UEDA Y, YAMAGISHI T, SAMATA K et al.: A novel low molecular weight VEGF receptor-binding antagonist, VGA1102, inhibits the function of VEGF and in vivo tumor growth. Cancer Chemother. Pharmacol. (2004) 54(1):16-24.
72. INAI T, MANCUSO M, HASHIZUME H et al.: Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am. J. Pathol. (2004) 165(1):35-52.
73. FILLEUR S, COURTIN A, AIT-SI-ALI S et al.: SiRNA-mediated inhibition of vascular endothelial growth factor severely limits tumor resistance to antiangiogenic thrombospondin-1 and slows tumor vascularization and growth. Cancer Res. (2003) 63(14):3919-3922.
74. DUXBURY MS, MATROS E, ITO H et al.: Systemic siRNA-mediated gene silencing: a new approach to targeted therapy of cancer. Ann. Surg. (2004) 240(4):667-674; discussion 675-666.
75. AHARINEJAD S, PAULUS P, SIOUD M et al.: Colony-stimularing facror-1 blockade by antisense oligonucleotides and small interfering RNAs suppresses growrh of human mammary tumor xenografts in mice. Cancer Res. (2004) 64(15):5378-5384.
76. LAKKA SS, GONDI CS, YANAMANDRA N et al.: Inhibition of cathepsin B and MMP-9 gene expression in glioblastoma cell line via RNA interference reduces tumor cell invasion, tumor growth and angiogenesis. Oncogene (2004) 23(27):4681-4689.
77. CHAE SS, PAIK JH, FURNEAUX H, HLA T: Requirement for sphingosine 1-phosphate receptor-1 in tumor angiogenesis demonstrated by in vivo RNA interference. J. Clin. Invest. (2004) 114(8):1082-1089.
78. TAKEI Y, KADOMATSU K, YUZAWA Y, MATSUO S, MURAMATSU T: A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics. Cancer Res. (2004) 64(10):3365-3370.
79. SCHIFFELERS RM, ANSARI A, XU J et al.: Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res. (2004) 32(19):e149.
80. KIM B, TANG Q, BISWAS PS et al.: Inhibition of ocular angiogenesis by siRNA targeting vascular endothelial growth factor-pathway genes; therapeutic strategy for herpetic stromal keratitis. Am. J. Pathol. (2004) 165(6):2177-2185.
81. JACKSON AL, BARTZ SR, SCHELTER J et al.: Expression profiling reveals off-target gene regulation by RNAi. Nat. Biotechnol. (2003) 21(6):635-637. One of the first reports questioning the specificity of RNAi.
82. SAXENA S, JONSSON ZO, DUTTA A: Small RNAs with imperfect match to endogenous mRNA repress translation. Implications for off-target activity of small inhibitory RNA in mammalian cells. J. Biol. Chem. (2003) 278(45):44312-44319.
83. SNOVE O JR, HOLEN T: Many commonly used siRNAs risk off-target activity. Biochem. Biophys. Res. Commun. (2004) 319(1):256-263.
84. SCACHERI PC, ROZENBLATT-ROSEN O, CAPLEN NJ et al.: Short interfering RNAs can induce unexpected and divergent changes in the levels of untargeted proteins in mammalian cells. Proc. Natl. Acad. Sci. USA (2004) 101(7):1892-1897.
85. ABBAS-TERKI T, BLANCO-BOSE W, DEGLON N, PRALONG W, AEBlSCHER P: Lentiviral-mediated RNA interference. Hum. Gene Ther. (2002) I3(18):2197-2201.
86. DEVROE E, SILVER PA: Retrovirus-delivered siRNA. BMC Biotechnol. (2002) 2(1):15.
87. TOMAR RS, MATTA H, CHAUDHARY PM: Use of adeno-associated viral vector for delivery of small interfering RNA. Oncogene (2003) 22(36):5712-5715.
88. CHIU YL, RANA TM: siRNA function in RNAi: a chemical modification analysis. RNA (2003) 9(9):1034-1048.
89. AMARZGUIOUI M, HOLEN T, BABAIE E, PRYDZ H: Tolerance for mutations and chemical modifications in a siRNA. Nucleic Acids Res. (2003) 31(2):589-595.
90. LAYZER JM, MCCAFFREY AP, TANNER AK et al.: In vivo activity of nuclease-resistant siRNAs. RNA (2004) 10(5):766-771.